Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
Agile Therapeutics (Nasdaq: AGRX) will release its Q1 2022 financial results on May 12, 2022, after market close. A live conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. Investors can dial in using (888) 330-2454 (U.S.) or (240) 789-2714 (international) with conference ID 7871426. The event will also be available for replay via the company's Investor Relations page.
- Scheduled Q1 2022 financial results announcement, offering potential insights into financial health.
- Opportunity for investors to engage in a live Q&A session during the conference call.
- None.
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2022 financial results after the market close on Thursday, May 12, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.
| Date | Thursday, May 12, 2022 |
| Time | 4:30 p.m. ET |
| Webcast (live and archived) | Events & Presentations |
| Dial-in numbers | (888) 330-2454 (U.S. toll-free) or (240) 789-2714 |
| Conference ID | 7871426 |
Investors interested in listening to the conference call may do so by dialing (888) 330-2454 for domestic callers or (240) 789-2714 for international callers. The Conference ID is 7871426. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.
Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
FAQ
What date will Agile Therapeutics announce its financial results?
What time is the conference call for Agile Therapeutics Q1 2022 results?
How can I participate in the Agile Therapeutics conference call?
Where can I find the webcast for Agile Therapeutics financial results?
What is the ticker symbol for Agile Therapeutics?
